Abivax SA

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: FR0012333284

EUR

108.20

-7.6 (-6.56%)

Dec 12

PAR

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Boiron SA

Eurobio-Scientific SA

Innate Pharma SA

AB Science SA

Nanobiotix SA

Abivax SA

PHAXIAM Therapeutics SA

Rougier SA

Gensight Biologics SA

Poxel SA

Biophytis SA

Why is Abivax SA ?

Flat results in Dec 24

OPERATING CASH FLOW(Y) Lowest at EUR -253.6 MM
OPERATING PROFIT(Q) Lowest at EUR -98.1 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 1354.30%, its profits have fallen by 0%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Abivax SA for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Abivax SA

1354.3%

0.95

520.28%

France CAC 40

8.73%

0.52

16.76%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-221.82%

EBIT to Interest (avg)

-13.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.22

Sales to Capital Employed (avg)

Tax Ratio

3.64%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

33.94%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-100.17

EV to EBIT

-26.20

EV to EBITDA

-26.36

EV to Capital Employed

-189.80

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Abivax SA

Net Profit

Higher at EUR -94.91 MM

than preceding 12 month period ended Dec 2024

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (EUR MM)

Debt-Equity Ratio

Lowest at -118.34 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Abivax SA

Operating Cash Flow

Lowest at EUR -253.6 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (EUR MM)

Operating Profit

Lowest at EUR -98.1 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (EUR MM)